Theravance Biopharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Theravance Biopharma announced the wind-down of its ampreloxetine program following Phase 3 study failure, accelerating a strategic review while focusing on YUPELRI's continued sales growth and cost-cutting restructuring.
NASDAQ
10-K: Theravance Biopharma Reports YUPELRI Sales Growth and Advances Ampreloxetine Phase 3 Trial in 2024
Theravance Biopharma's 2024 10-K filing highlights YUPELRI's net sales growth, continued progress in the Ampreloxetine Phase 3 clinical study, and a strategic review to unlock shareholder value.
NASDAQ
Theravance Biopharma's 2023 annual report showcases YUPELRI's sales growth and the advancement of ampreloxetine into a new Phase 3 clinical study.